SLAMF7/CRACC/CD319[Biotin], His & Avi, Human
| $660.00 | |
| Z04616-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $660.00 | |
| Z04616-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Conjugate | Biotin | ||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 25.3 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized SLAMF7/CRACC/CD319[Biotin], His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 2.6 ng/ml determined by ELISA. »
The purity of SLAMF7/CRACC/CD319[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
SLAMF7/CRACC/CD319[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family.Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. |
| Synonyms | CD2 subset 1; CRACC; Novel Ly9; CD319; SLAMF7; CS1; 19A; FOAP-12 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.